Therapeutic targets for diabetic nephropathy identified by druggable genome mendelian randomization: the role of the gut microbiota-metabolite axis - Scorecard - MDSpire
Advertisement
Therapeutic targets for diabetic nephropathy identified by druggable genome mendelian randomization: the role of the gut microbiota-metabolite axis
Clinical Scorecard: Identification of Therapeutic Targets for Diabetic Nephropathy through Mendelian Randomization of Druggable Genome: Exploring the Gut Microbiota-Metabolite Connection
At a Glance
Category
Detail
Condition
Key Mechanisms
Involvement of druggable genes, mTORC1 signaling, and gut microbiota-metabolite interactions linked to DN pathogenesis.
Target Population
Care Setting
Key Highlights
FOS and IL12A are nominated as key therapeutic targets for DN, with potential implications for treatment.
Guideline-Based Recommendations
Diagnosis
Management
Focus on druggable genes for targeted therapies in DN, including specific drug classes or mechanisms.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Novel therapeutic targets identified may lead to improved treatment strategies, including potential drug development.
Clinical Best Practices
Incorporate genetic and microbiome data in DN management, utilizing specific tools or methodologies.
Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare autosomal recessive condition that causes deficiency of the von Willebrand factor (vWF)-cleaving metalloprotease, ADAMTS13. Recombinant ADAMTS13 (rADAMTS13) is the first FDA-approved product for management of cTTP. This article reviews the pharmacology, pharmacokinetics, efficacy, safety, dosing, administration, and implications for advanced practitioners of rADAMTS13.
